1-3 of 3
Susan M Perkins
Close
Sort by
Journal Articles

Minimal Intensity Fludarabine/Cyclophosphamide Versus Myeloablative Thiotepa/Cyclophosphamide Followed By Allogeneic Hematopoetic Stem Cell Transplantation (HSCT) for the Treatment of Acute Myeloid Leukemia (AML)— a Retrospective Single Institution Experience

Nabin Khanal, MBBS, Brian E Johnson, MD, H. Scott Boswell, MD, Heiko Konig, MDPhD, Susan M Perkins, PhD, Robert P. Nelson, Jr., MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5471.
https://doi.org/10.1182/blood.V130.Suppl_1.5471.5471
Published: 2017
Journal Articles

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Attaya Suvannasankha, MD, Rafat Abonour, MD, Sherif Farag, MD PhD, Rebecca W. Silbermann, MD, Sariya Wongsaengsak, MD, Mary Helen Cangany, RN, Anita Rush-Taylor, RN, Mark Tann, MD, Sandra K Althouse, PhD, Susan M Perkins, PhD, G David Roodman, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1826.
https://doi.org/10.1182/blood.V130.Suppl_1.1826.1826
Published: 2017
Journal Articles

Multiplex Cytokine Analysis after Cyclophosphamide/Fludarabine Nonmyeloablative Allogeneic Hematopoeitic Cell Transplantation

Muhammad Rizwan Khawaja, MD, Christie M. Orschell, PhD, Brandon M. Hardesty, MD, Brice C Burke, MS, Susan M Perkins, Robert Nelson
Journal: Blood
Blood (2014) 124 (21): 1148.
https://doi.org/10.1182/blood.V124.21.1148.1148
Published: 2014